Firategrast-natalizumab in a pill?

The Lancet Neurology

Volumn 11, Issue 2, 2012, Pages 120-121

  Prat, Alexandre ^a,b   Stüve, Olaf ^c,d  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; FIRATEGRAST; GADOLINIUM; HETERODIMER; NATALIZUMAB; PLACEBO; VERY LATE ACTIVATION ANTIGEN 4;

B LYMPHOCYTE; BONE MARROW CELL; BRAIN DAMAGE; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM INFECTION; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; LEUKOCYTE MIGRATION; LYMPHOCYTE; MONOCYTE; MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PILL; POLYOMA VIRUS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN BINDING; PROTEIN EXPRESSION; URINARY TRACT INFECTION;

ANIMALS; CELL MOVEMENT; HUMANS; IMMUNOTHERAPY; INFLAMMATION;

EID: 84855987220     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70306-4     Document Type: Letter

References (9)

1. Luster AD, Alon R, von Andrian UH Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 2005, 6:1182-1190.
2. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
3. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911-923.
4. Medical Information Biogen idec, (accessed Dec 17, 2011). https://medinfo.biogenidec.com.
5. Miller DH, Weber T, Grove R, et al. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2012, publised online Jan 6. 10.1016/S1474-4422(11)70299-X.
6. Sheremata WA, Vollmer TL, Stone LA, Willmer-Hulme AJ, Koller M A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 1999, 52:1072-1074.
7. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348:15-23.
8. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009, 72:402-409.
9. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006, 59:743-747.